Featured Press Releases

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

Shorla Oncology Announces the Launch of Dedicated Sales Force and Market Access Teams as Part of Expansion of Its U.S. Commercial Footprint

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

  • 27 Jun 2024

CalciMedica Inc. a clinical-stage biopharmaceutical company focused on developing novel calcium...

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

PCI Pharma Buys Ajinomoto Althea as Part of $1B Plan to Expand Injectable Drug Manufacturing in the U.S

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

Research from Noster finds that a gut bacteria-derived molecule can shrink fat cells and improve metabolism

Research from Noster finds that a gut bacteria-derived molecule can shrink fat cells and improve metabolism

Fast-Acting Covalent Protein Drugs Developed from a New High-Throughput Platform

Fast-Acting Covalent Protein Drugs Developed from a New High-Throughput Platform

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026
Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

  • Upsher-Smith Laboratories, LLC
  • 21 Aug 2026
Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

  • Dunbar Pharmaceuticals
  • 18 Aug 2026
Former DePuy Synthes U.S. President Joins Peptilogics Board

Former DePuy Synthes U.S. President Joins Peptilogics Board

  • Peptilogics
  • 18 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.